Cargando…

Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration

Detalles Bibliográficos
Autor principal:	Gopal, Lingam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672751/ https://www.ncbi.nlm.nih.gov/pubmed/35918963 http://dx.doi.org/10.4103/ijo.IJO_753_22

Ejemplares similares

Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration
por: Shah, Chirag, et al.
Publicado: (2023)

A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis(®) in patients with neovascular age-related macular degeneration
por: Singh, Ramandeep, et al.
Publicado: (2022)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
por: Scalzo, G C, et al.
Publicado: (2010)

Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration
por: Reis, Gustavo MSM, et al.
Publicado: (2017)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis(®))
por: Horowitz, Soraya Alessandra, et al.
Publicado: (2020)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
por: Merz, Patrick R., et al.
Publicado: (2018)

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
por: Maunz, Andreas, et al.
Publicado: (2023)

Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar
por: Kim, Eunji, et al.
Publicado: (2022)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration
por: Nita, Małgorzata, et al.
Publicado: (2014)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
por: Gohil, Rishma, et al.
Publicado: (2015)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
por: Russo, Andrea, et al.
Publicado: (2018)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova, Nadezhda P, et al.
Publicado: (2016)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment
por: Andric, Marko, et al.
Publicado: (2013)

Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma
por: Zhao, Xuli, et al.
Publicado: (2022)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
por: Sabour-Pickett, Sarah, et al.
Publicado: (2013)

Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration§
por: Guber, Josef, et al.
Publicado: (2014)

Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration
por: Lee, Kang Hoon, et al.
Publicado: (2015)

Missed Hospital Appointments of Patients Receiving Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
por: Karampelas, Michael, et al.
Publicado: (2015)

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
por: Wang, Luping, et al.
Publicado: (2018)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont, Pear, et al.
Publicado: (2018)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
por: Rodríguez, Francisco Jose, et al.
Publicado: (2019)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration
por: Diack, Cheikh, et al.
Publicado: (2021)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Long-term results of intravitreal ranibizumab for osteoma-related choroidal neovascularization in a child
por: Gupta, Aditi, et al.
Publicado: (2014)

Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment
por: Mitchell, Paul, et al.
Publicado: (2014)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar, Prasad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vr4gus03bb8oh5hdeegb074v85